Effect of acupuncture treatment on Vascular Cognitive Impairment, No Dementia

Not Applicable

Completed

• Conditions: Vascular cognitive impairment not dementia(VCIND); Mental and Behavioural Disorders

• Registration Number: ISRCTN82980206
• Lead Sponsor: Beijing Municipal Science & Technology Commission (China)

Brief Summary

2014 protocol in: http://www.ncbi.nlm.nih.gov/pubmed/25391431 2019 results in: http://www.ncbi.nlm.nih.gov/pubmed/30672317 [added 18/02/2019]

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-01-17
• Study Completion: 2016-10-30
• Last Update Posted: 25 March 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 216

Inclusion Criteria

1. Aged 55-85 years, either sex
2. Hachinski score =7
3. Evidence of vascular lesions on neuroradiology
4. Fluency in language sufficient to reliably complete all study assessments
5. Mini-Mental State Examination (MMSE) score >dementia threshold corrected based on educational year (>17 scores, >20 scores and >24 scores for 0, =6, and>6 educational years, respectively)
6. Montreal Cognitive Assessment (MoCA) <26 scores for >12 educational years (or <25 scores for=12 educational years)
7. Written and informed consent

Exclusion Criteria

1. History of mental diseases (e.g., schizophrenia, serious anxiety and depression)
2. Patients with Alzheimer's disease, Parkinson's disease, frontotemporal dementia or Huntington's disease
3. Patients with epilepsy and/or ever having antiepileptic drugs
4. Presence of serious heart diseases, kidney diseases or liver diseases

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The cognitive section of the Alzheimer Disease Assessment Scale (ADAS-Cog) will be assessed at baseline, the end of treatment and 3 months after the end of treatment.

Secondary Outcome Measures

Name	Time	Method
<br> 1. Clock drawing test (CDT) will be assessed at baseline, the end of treatment and 3 months after the end of treatment.<br> 2. Ability of daily living (ADL) and instrumental activities of daily living scale (IADL) will be assessed at baseline, the end of treatment and 3 months after the end of treatment.<br><br> Participants will report adverse events they experience, including discomfort or bruising at the sites of needle insertion, nausea, or feeling faint after each acupuncture treatment. Adverse drug reactions like nausea and vomiting, dizziness, dry mouth and itching will also be recorded.<br>